|
Safety and Efficacy of MBI 226 for the Prevention of Central Venous Catheter-related Bloodstream Infections Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for proven healthcare advice, travels to or treatment by using a genuine medical doctor. We are not physicians. Always confer with your doctor on Safety and Efficacy of MBI 226 for the Prevention of Central Venous Catheter-related Bloodstream Infections conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Safety and Efficacy of MBI 226 for the Prevention of Central Venous Catheter-related Bloodstream Infections Clinical research trials and Safety and Efficacy of MBI 226 for the Prevention of Central Venous Catheter-related Bloodstream Infections healthcare trials take place in many of cities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the effectiveness of new drugs. The function of the studies / undertakings is to answer specific human medical questions. Clinical trials are a popular means for mDs, government agencies, and private sector companies to find treatments for all forms of conditions, including Safety and Efficacy of MBI 226 for the Prevention of Central Venous Catheter-related Bloodstream Infections. Safety and Efficacy of MBI 226 for the Prevention of Central Venous Catheter-related Bloodstream Infections Clinical Trials and other clinical trials allow for volunteers to access medical treatment alternatives before they are available to the masses. Many times the test subjects undergo treatment for without cost, and occasionally they are compensated for their time. Occasionally there is a cost for a Safety and Efficacy of MBI 226 for the Prevention of Central Venous Catheter-related Bloodstream Infections clinical trial. Test subjects oftentimes recieve the best healthcare possible for their Safety and Efficacy of MBI 226 for the Prevention of Central Venous Catheter-related Bloodstream Infections condition. Hazards are a reality, nonetheless, and might include additional or frequent doctor trips, healthcare hazards (perhaps life-jeopardizing), and/or the treatment being ineffective. Trials are federally regulated with rigid guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > Safety and Efficacy of MBI 226 for the Prevention of Central Venous Catheter-related Bloodstream Infections  Safety and Efficacy of MBI 226 for the Prevention of Central Venous Catheter-related Bloodstream Infections
Safety and Efficacy of MBI 226 for the Prevention of Central Venous Catheter-related Bloodstream Infections
For Condition: Sepsis,Bacteremia,Fungemia
Status: Completed
Sponsor(s): Micrologix Biotech ,
Synopsis: Central venous catheters (CVCs) are used in patient care for such purposes as the administration of medication, fluids, blood products and for functions such as hemodialysis and plasmapheresis. However, the use of CVCs can cause complications such as life-threatening bloodstream infections (BSI). BSIs are caused by organisms from the skin's surface tracking down the catheter's outer surface. The organisms grow on the catheter surface (catheter colonization) which is followed by seeding into the bloodstream. BSIs can be difficult to treat and the mortality rate is as high as 35% in Intensive Care patients with a catheter-related BSI. It is estimated that up to 70,000 patients in the US die each year from catheter-related BSI. MBI 226 is a new drug that, when applied to the skin surrounding the catheter insertion site, will prevent organisms on the skin from migrating down the catheter and entering the bloodstream and therefore decrease the incidence of catheter-related BSI in patients with CVCs.
Details:
Eligibility:
Study Type: Interventional, Prevention, Randomized, Double-Blind, Active Control, Single Group Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 16 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Patients undergoing non-cuffed arterial and/or central venous catheterization. - Patients able to give signed informed consent. - Concurrent antibiotic therapy is permitted. Exclusion Criteria: - Treatment with an experimental topical, antibacterial, or antifungal drug within the previous 30 days. - Patients who are scheduled to receive catheters impregnated/bonded with an antimicrobial substance. - Patients requiring arterial or central venous catheterization for less than 48 hours or longer than 28 days. - Second or third degree burn patients. - Patients with a suspected or known bloodstream infection or local catheter insertion site infection. - Patients with a known allergy to adhesive tape or adhesive bandages. - Patients with a medical condition that the Investigator believes may interfere with the safety of the patient or the intent or conduct of the study. - Routine non-complicated post-operative CABG patients. - The disinfection procedure for catheter insertion did not include povidone-iodine.
Total Enrollment: 1400
Location and Contact Information:
Omnicare Clinical Research Inc.
Lake Bluff, Illinois, 60044
United States
Additional Information:
Study ID Numbers: 226-98-002;
Study Start Date: September 2000
Record last reviewed: July 2002
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00027248
Other Sepsis Studies:
1. An Open Label, Non-Comparative, Multicenter, Phase III Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infections
2. Comparing the Effectiveness of Fluconazole and a New Medicine (FK463) in Preventing Fungal Infections in Bone Marrow Transplant Patients
3. Safety and Efficacy of MBI 226 for the Prevention of Central Venous Catheter-related Bloodstream Infections
Related Studies:
Other Sepsis Clinical Trials
Other Illinois Clinical Trials
Other Lake Bluff Clinical Trials
Safety and Efficacy of MBI 226 for the Prevention of Central Venous Catheter-related Bloodstream Infections
|
|
|
|
|
|
|
|
